GSK-2793660 is an orally active and irreversible inhibitor of Cathepsin C ( CTSC ). GSK-2793660 can be used for the research of bronchiectasis [1] [2].
In Vivo, GSK-2793660 is a cathepsin C (also known as dipeptidyl peptidase I enzyme) inhibitor for the reaearch of cystic fibrosis, non-cystic fibrosis bronchiectasis, anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis and bronchiectasis[1].
References:
[1]. Szcześniak P, et al. The Synthesis of α,α-Disubstituted α-Amino Acids via Ichikawa Rearrangement. J Org Chem. 2016;81(3):1057-1074.
[2]. Miller BE, et al. Epithelial desquamation observed in a phase I study of an oral cathepsin C inhibitor (GSK2793660). Br J Clin Pharmacol. 2017;83(12):2813-2820.
In Vivo, GSK-2793660 is a cathepsin C (also known as dipeptidyl peptidase I enzyme) inhibitor for the reaearch of cystic fibrosis, non-cystic fibrosis bronchiectasis, anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis and bronchiectasis[1].
References:
[1]. Szcześniak P, et al. The Synthesis of α,α-Disubstituted α-Amino Acids via Ichikawa Rearrangement. J Org Chem. 2016;81(3):1057-1074.
[2]. Miller BE, et al. Epithelial desquamation observed in a phase I study of an oral cathepsin C inhibitor (GSK2793660). Br J Clin Pharmacol. 2017;83(12):2813-2820.